-
-
-
-
-
-
-
Regulus Therapeutics Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis in Collaboration with Researchers from Harvard's Brigham and Women's Hospital
-
-
-
-
-
-
-
Regulus Therapeutics (RGLS) Announces Completion of Enrollment in First Cohort of Phase 1b MAD Clinical Trial of RGLS8429 for Treatment of Patients with ADPKD
-
-
-
-
-
-
-
Regulus Therapeutics (RGLS) Reports In-Line Q3 EPS
-
-
-
-
-
-
-
Regulus Therapeutics to Participate in Upcoming Investor Conferences
-
-
-
-
-
-
-
Regulus Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates
-
-
-
-
-
-
-
Regulus Therapeutics Announces Timing for Fourth Quarter and Year-End 2021 Financial Results Webcast and Conference Call
-
-
-
-
-
-
-
Regulus Therapeutics Announces Presentation at the First Annual Rare & Genetic Kidney Disease Drug Development Summit
-
968,303 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All